https://www.onhealthcare.tech/p/isomorphic-labs-pulls-21b-series-6c0Thoughts on Healthcare Markets & Technologyen2026-05-14T11:54:57+00:00Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital Stack, IsoDDE Engine, And Novartis/Lilly/J&J Partnerships Mean For Drug Discoveryhttps://www.onhealthcare.tech/p/isomorphic-labs-pulls-21b-seriesThoughts on Healthcare Markets & Technologyen2026-05-14T11:45:38+00:00Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital Stack, IsoDDE Engine, And Novartis/Lilly/J&J Partnerships Mean For Drug Discoveryhttps://www.onhealthcare.tech/p/why-the-q1-2026-payer-margin-reboundThoughts on Healthcare Markets & Technologyen2026-05-13T13:40:29+00:00Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene, & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits & Tighter Utilization Mgmthttps://www.onhealthcare.tech/p/part-ii-why-the-q1-2026-payer-marginThoughts on Healthcare Markets & Technologyen2026-05-13T01:34:35+00:00Part II: Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits & Tighter Utilization Mgmthttps://www.onhealthcare.tech/p/part-i-why-the-q1-2026-payer-marginThoughts on Healthcare Markets & Technologyen2026-05-13T01:32:14+00:00Part I: Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits, & Tighter Utilization Mgmt